banner

News Releases

Date Title and Summary  
Toggle Summary ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO --(BUSINESS WIRE)--Sep. 20, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
- Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis - Pimavanserin has the potential to be the first FDA -approved drug for the treatment of dementia-related psychosis - Approximately 1.2 million
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the promotion of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Sep. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
- Pimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms (p=0.0940) - Significant improvements observed on secondary endpoint of PANSS negative symptoms scale sub-score (unadjusted p=0.0474) - Conference call
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Sep. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
- 1Q19 Net Sales Grew to $63.0 Million , a 29% Increase Over 1Q18 - Updated 2019 Net Sales Guidance to $280 Million to $300 Million - Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies with Pimavanserin SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- Fourth Quarter 2018 Net Sales Grew to $59.6 Million , a 37% Increase Over 4Q17 - Full Year 2018 Net Sales Grew to $223.8 Million , a 79% Increase Over Full Year 2017 - Late Stage Pipeline Progressing with Five Clinical Programs Ongoing or Commencing in 2019 - 2019 Guidance: Net Sales $275 Million
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
- 2Q19 Net Sales Grew to $83.2 Million , a 46% Increase Over 2Q18 - 2019 Net Sales Guidance Increased to $320 Million to $330 Million SAN DIEGO --(BUSINESS WIRE)--Jul. 31, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
SAN DIEGO --(BUSINESS WIRE)--Apr. 11, 2019-- ACADIA Pharmaceuticals Inc . (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced support of several
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
ACADIA to Host Conference Call and Webcast on Wednesday, May 1, 2019 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
ACADIA to Host Conference Call and Webcast on Tuesday, February 26, 2019 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 12, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
ACADIA to Host Conference Call and Webcast on Wednesday, July 31, 2019 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
SAN DIEGO --(BUSINESS WIRE)--Apr. 2, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
SAN DIEGO --(BUSINESS WIRE)--Feb. 21, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO --(BUSINESS WIRE)--May 7, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--Jun. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
— New data presented at the International Congress of Parkinson’s Disease and Movement Disorders will highlight treatment benefit of pimavanserin in patients with comorbid Parkinson’s disease and depression — New data presented at the Psych Congress will highlight improvement on sexual functioning
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
SAN DIEGO --(BUSINESS WIRE)--May 18, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from
Printer Friendly Version
Toggle Summary New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
- "Parkinson's IQ + You" events are designed to empower people with Parkinson's and care partners to manage the disease, learn about research participation and connect with local resources - This series of events is presented by The Michael J. Fox Foundation and funded by ACADIA Pharmaceuticals,
Printer Friendly Version
Toggle Summary Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome -- Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in Europe SAN DIEGO & CINCINNATI & MELBOURNE, Australia --(BUSINESS
Printer Friendly Version